PharmaCyte Biotech Inc
PMCB0.765USD
-0.005-0.68%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
5.20MMarket Cap
LossP/E TTM
More Details of PharmaCyte Biotech Inc Company
PharmaCyte Biotech, Inc. is a biotechnology company, which is focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.
PharmaCyte Biotech Inc Info
Ticker SymbolPMCB
Company namePharmaCyte Biotech Inc
IPO dateSep 11, 2003
CEOSilverman (Joshua N)
Number of employees2
Security typeOrdinary Share
Fiscal year-endSep 11
Address3960 Howard Hughes Parkway, Suite 500
CityLAS VEGAS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code89169
Phone19175952850
Websitehttps://pharmacyte.com/
Ticker SymbolPMCB
IPO dateSep 11, 2003
CEOSilverman (Joshua N)
Company Executives of PharmaCyte Biotech Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Jonathan L. Schechter
Mr. Jonathan L. Schechter
Independent Director
Independent Director
50.00K
--
Mr. Carlos A. Trujillo, CPA
Mr. Carlos A. Trujillo, CPA
Chief Financial Officer
Chief Financial Officer
10.40K
--
Dr. Michael M. Abecassis, M.D.
Dr. Michael M. Abecassis, M.D.
Independent Director
Independent Director
--
--
Mr. Wayne R. Walker
Mr. Wayne R. Walker
Independent Director
Independent Director
--
--
Mr. Robert Weinstein
Mr. Robert Weinstein
Independent Director
Independent Director
--
--
Mr. Joshua N. (Josh) Silverman
Mr. Joshua N. (Josh) Silverman
Interim Chairman of the Board, Interim Chief Executive Officer and Interim President
Interim Chairman of the Board, Interim Chief Executive Officer and Interim President
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Jonathan L. Schechter
Mr. Jonathan L. Schechter
Independent Director
Independent Director
50.00K
--
Mr. Carlos A. Trujillo, CPA
Mr. Carlos A. Trujillo, CPA
Chief Financial Officer
Chief Financial Officer
10.40K
--
Dr. Michael M. Abecassis, M.D.
Dr. Michael M. Abecassis, M.D.
Independent Director
Independent Director
--
--
Mr. Wayne R. Walker
Mr. Wayne R. Walker
Independent Director
Independent Director
--
--
Mr. Robert Weinstein
Mr. Robert Weinstein
Independent Director
Independent Director
--
--
Mr. Joshua N. (Josh) Silverman
Mr. Joshua N. (Josh) Silverman
Interim Chairman of the Board, Interim Chief Executive Officer and Interim President
Interim Chairman of the Board, Interim Chief Executive Officer and Interim President
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Dec 14
Updated: Sun, Dec 14
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Intracoastal Capital, L.L.C.
5.20%
Schechter (Jonathan L)
1.31%
Geode Capital Management, L.L.C.
1.25%
Equitec Proprietary Markets, LLC
0.82%
Asher (Daniel B)
0.82%
Other
90.61%
Shareholders
Shareholders
Proportion
Intracoastal Capital, L.L.C.
5.20%
Schechter (Jonathan L)
1.31%
Geode Capital Management, L.L.C.
1.25%
Equitec Proprietary Markets, LLC
0.82%
Asher (Daniel B)
0.82%
Other
90.61%
Shareholder Types
Shareholders
Proportion
Corporation
5.20%
Individual Investor
3.56%
Investment Advisor
1.58%
Investment Advisor/Hedge Fund
1.44%
Hedge Fund
1.25%
Research Firm
0.02%
Other
86.96%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
61
457.38K
6.73%
-604.80K
2025Q2
66
1.28M
18.72%
-522.91K
2025Q1
71
1.30M
18.90%
-631.78K
2024Q4
75
1.52M
21.80%
-704.25K
2024Q3
81
1.75M
23.16%
-1.87M
2024Q2
84
1.91M
21.34%
-3.77M
2024Q1
81
1.85M
20.70%
-3.82M
2023Q4
82
1.98M
21.84%
-3.87M
2023Q3
81
2.90M
23.35%
-2.45M
2023Q2
83
2.99M
16.94%
-4.58M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Intracoastal Capital, L.L.C.
527.38K
1.12%
--
--
Dec 31, 2024
Schechter (Jonathan L)
50.00K
0.11%
--
--
Sep 15, 2025
Geode Capital Management, L.L.C.
126.60K
0.27%
-12.33K
-8.88%
Jun 30, 2025
Equitec Proprietary Markets, LLC
82.73K
0.18%
--
--
Jun 30, 2025
Asher (Daniel B)
82.73K
0.18%
--
--
Dec 31, 2024
Renaissance Technologies LLC
49.80K
0.11%
+300.00
+0.61%
Jun 30, 2025
The Vanguard Group, Inc.
194.45K
0.41%
-71.00
-0.04%
Jun 30, 2025
Silverman (Joshua N.)
50.00K
0.11%
--
--
Sep 15, 2025
Schonfeld Strategic Advisors LLC
26.20K
0.06%
+700.00
+2.75%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of PharmaCyte Biotech Inc?
The top five shareholders of PharmaCyte Biotech Inc are:
Intracoastal Capital, L.L.C. holds 527.38K shares, accounting for 1.12% of the total shares.
Schechter (Jonathan L) holds 50.00K shares, accounting for 0.11% of the total shares.
Geode Capital Management, L.L.C. holds 126.60K shares, accounting for 0.27% of the total shares.
Equitec Proprietary Markets, LLC holds 82.73K shares, accounting for 0.18% of the total shares.
Asher (Daniel B) holds 82.73K shares, accounting for 0.18% of the total shares.
Intracoastal Capital, L.L.C. holds 527.38K shares, accounting for 1.12% of the total shares.
Schechter (Jonathan L) holds 50.00K shares, accounting for 0.11% of the total shares.
Geode Capital Management, L.L.C. holds 126.60K shares, accounting for 0.27% of the total shares.
Equitec Proprietary Markets, LLC holds 82.73K shares, accounting for 0.18% of the total shares.
Asher (Daniel B) holds 82.73K shares, accounting for 0.18% of the total shares.
What are the top three shareholder types of PharmaCyte Biotech Inc?
The top three shareholder types of PharmaCyte Biotech Inc are:
Intracoastal Capital, L.L.C.
Schechter (Jonathan L)
Geode Capital Management, L.L.C.
Intracoastal Capital, L.L.C.
Schechter (Jonathan L)
Geode Capital Management, L.L.C.
How many institutions hold shares of PharmaCyte Biotech Inc (PMCB)?
As of 2025Q3, 61 institutions hold shares of PharmaCyte Biotech Inc, with a combined market value of approximately 457.38K, accounting for 6.73% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -11.99%.
What is the biggest source of revenue for PharmaCyte Biotech Inc?
In --, the -- business generated the highest revenue for PharmaCyte Biotech Inc, amounting to -- and accounting for --% of total revenue.
